Literature DB >> 3856037

Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles.

C B Brendler, A L Follansbee, J T Isaacs.   

Abstract

A relative enzymatic index has been developed which differentiates normal, hyperplastic (BPH) and malignant human prostatic tissues. Enzymatic activities have been calculated at Vmax conditions in 10 normal, 14 BPH and 11 carcinoma samples. Five enzymes have been assayed: 1) 5 alpha-reductase, 2) 3 alpha-hydroxysteroid oxidoreductase, 3) 3 beta-hydroxysteroid oxidoreductase, 4) 17 beta-hydroxysteroid oxidoreductase and 5) acid phosphatase. The following observations were made when comparing individual enzymatic activities between the 3 tissue groups: 1) mean 5 alpha-reductase activity was lower in carcinoma than in both normal prostate and BPH (p less than 0.05), 2) mean 3 alpha-hydroxysteroid oxidoreductase and 3 beta-hydroxysteroid oxidoreductase activities were greater in carcinoma than in BPH (p less than 0.05) and 3) mean acid phosphatase activity was higher in BPH than in both normal prostate and carcinoma (p less than 0.01). The absolute enzymatic activities were then expressed as relative activities by dividing each absolute value by the mean value for that enzyme in normal prostatic tissue. Relative enzymatic activities were used to derive the ratio: (Formula: see text) The mean value of this ratio was statistically different in normal, BPH and carcinoma tissue (p less than 0.01). The mean value was 3.6 times higher in BPH than in normal tissue, and was 3.8 times higher in normal tissue than in carcinoma. This suggests that BPH and carcinoma diverge in opposite directions biochemically from normal prostatic growth and supports histologic evidence that the 2 neoplastic conditions have a different pathogenesis rather than being part of the same disease spectrum.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3856037     DOI: 10.1016/s0022-5347(17)49040-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.

Authors:  A E Thigpen; R I Silver; J M Guileyardo; M L Casey; J D McConnell; D W Russell
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

Review 2.  Cytokine and endocrine signaling in prostate cancer.

Authors:  J Puente Vazquez; E Grande Pulido; L M Anton Aparicio
Journal:  Med Oncol       Date:  2011-08-20       Impact factor: 3.064

Review 3.  Androgen-receptor gene structure and function in prostate cancer.

Authors:  J M Hakimi; R H Rondinelli; M P Schoenberg; E R Barrack
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 4.  Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.

Authors:  Kalyan J Gangavarapu; Peter F Jowdy; Barbara A Foster; Wendy J Huss
Journal:  Am J Clin Exp Urol       Date:  2022-06-15

5.  Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.

Authors:  Tomoe Fujita; Yoshiaki Matsumoto; Toshimi Kimura; Shinichi Yokota; Mika Sawada; Masataka Majima; Yoshio Ohtani; Yuji Kumagai
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.